Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recruiting × Lymphangioma × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 17 Carcinoma, Non-Small-Cell Lung 12 Leukemia, Myeloid, Acute 9 Squamous Cell Carcinoma of Head and Neck 8 Prostatic Neoplasms 8 Pancreatic Neoplasms 8 Colorectal Neoplasms 8 Neoplasm Metastasis 7 Myasthenia Gravis 7 Breast Neoplasms 7 Stomach Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Carcinoma, Hepatocellular 6 Recurrence 5 Lung Neoplasms 5 Leukemia 5 Hematologic Neoplasms 5 Urinary Bladder Neoplasms 4 Ovarian Neoplasms 4 Neoplasms, Plasma Cell 4 Multiple Myeloma 4 Melanoma 4 Lymphoma 4 Infections 4 Head and Neck Neoplasms 4 Fatigue 4 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 3 Rectal Neoplasms 3 Neuroendocrine Tumors 3

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡